CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3555817
• 负责人: JAMES F HOLLAND
• 金额: $ 7.34万
• 依托单位: MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555817
• 关键词: 6 thiopurine; Hodgkin's disease; MHC class II antigen; Mycobacterium bovis; acute leukemia; acute lymphocytic leukemia; adult human (21+); asparaginase; breast neoplasms; carmustine; chlorambucil; chloroquine; chronic leukemia; chronic myelogenous leukemia; combination cancer therapy; cooperative study; cyclophosphamide; cytosine arabinoside; daunorubicin; doxorubicin; drug adverse effect; histiocytic lymphoma; human subject; human therapy evaluation; immunoglobulins; immunologic skin test; lomustine; lymphocytic leukemia; lymphoma; lymphosarcoma; methotrexate; multiple myeloma; myelogenous leukemia; myeloma globulin; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; nephroblastoma; pediatric neoplasm /cancer; prednisone; procarbazine; protein biosynthesis; splenectomy; urea; vincristine

Mount Sinai intends to continue its vigorous participation in activities with the Cancer and Leukemia Group B. We will commit intellectual and patient resources to research in acute leukemias, chronic leukemias, lymphomas, breast cancer, respiratory cancers, and companion studies with these clinical under takings involving cytogenetics, immunology and epidemiology. Various members of the Mount Sinai faculty will serve as Chairman of Studies, and bring some of their pilot observations conducted in the Mount Sinai Cancer Center to Group consideration. If adopted, such studies will serve as the feasibility pilot background for implementation on a broad multi- institutional basis, often in a comparative randomized study design. The objectives of the Group are to discover and validate effective treatment for the cure and long term palliation of cancer. Mount Sinai is wholeheartedly committed to these objectives, and will devote energy to make the most effective studies available to the Group for research purposes.

西奈山打算继续剧烈参与 癌症和白血病组的活动。我们将 将智力和患者资源进行急性研究 白血病，慢性白血病，淋巴瘤，乳腺癌， 呼吸癌和与这些临床的同伴研究 在涉及细胞遗传学，免疫学和 流行病学。 西奈山的各个成员将 担任研究主席，并带来一些飞行员 在西奈山癌症中心进行的观察 小组考虑。 如果采用，此类研究将作为 可行性试点背景，用于实施广泛 机构基础，通常在比较随机研究中 设计。 小组的目标是发现和验证 有效治疗和长期治愈的治疗方法 癌症。 西奈山全心全意地致力于这些 目标，并将投入能量来使最有效 该小组可用于研究目的的研究。